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Abstract: Hematopoietic stem cell transplantation may “reset” the immune reconstitution 
and induce self tolerance of autoreactive lymphocytes, and has been explored in the treatments 
for systemic sclerosis. Phase I/II trials have shown a satisfactory risk benefit ratio. The true 
benefit will be identified by two ongoing prospective, randomized phase III trials. Multipotent 
mesenchymal stromal cells (MSCs) possess antiproliferative, anti-inflammatory, and immu-
nosuppressive properties. The use of MSCs has showed successful responses in patients with 
severe steroid-resistant acute graft versus host disease in phase II trials, and may be a potentially 
promising option for patients with systemic sclerosis.
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Introduction
Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disorder manifested 
by excess synthesis and deposition of collagen (both type I and III) in skin and 
visceral organs, vascular abnormalities and autoimmunity.1 Physically debilitating, 
scleroderma is associated with a 5- to 8-fold increase in mortality over that of the 
general population.2 High skin score, pulmonary, renal, or cardiac involvement is 
associated with a higher mortality of 40% to 50% within 5 years.3–7 The pathogenesis 
of SSc is extremely complex, which involves interactions between endothelial cells, 
epithelium, immunological mediators, lymphocytes, and fibroblasts. The functional 
alterations in these cells result in three characteristic changes in SSc: dysregulated 
vascular remodeling and, ultimately, vasculopathy with obliteration of the lumen of 
small arteries and arterioles; humoral and cellular immunologic abnormalities; and 
progressive cutaneous and visceral fibrosis.8 Endothelial cell injury is an early and 
probably initiating event, although the precise etiology remains unclear. Endothelin-1 
(ET-1) is believed to be a potent mediator of vasculopathy, and therefore represents a 
potentially therapeutic target.9 To date, there is no single therapeutic agent proven to 
be universally effective, although several studies have shown that cyclophosphamide 
may improve skin thickening and lung fibrosis, and the efficacy of mycophenolate 
mofetil in scleroderma-related interstitial lung disease has also been described.10–12 The 
European League Against Rheumatism (EULAR) Scleroderma Trials and Research 
group (EUSTAR) published a set of core recommendations for treatment of SSc based 
on clinical research evidence in published literature, expert opinion, and clinical 
experience. The EULAR guidelines recommend assessing the patient for organ systems 
involved, and on the basis of this assessment, suggest using cyclophosphamide for lung 
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disease or methotrexate for skin disease. Mycophenolate 
mofetil and azathioprine are good alternative treatments for 
lung disease; methotrexate is the most appropriate treatment 
for scleroderma overlap condition.13 ET-1 antagonists and 
sildenafil are supported by randomized trials on scleroderma 
associated pulmonary hypertension and possibly digital 
ulcerations. Most recently, new drugs such as relaxin, 
pirfenidone, halofuginone, tyrosine kinase inhibitors, anti-
TGF-b antibodies, and histone deacetylase-7 inhibitor have 
been used as antifibrotic agents in the treatment of SSc, 
in some cases with promising results.14,15
Hematopoietic stem cell transplantation (HSCT) is a 
potential therapy for patients with severe and refractory 
autoimmune disease. It is proposed to possibly “reset” the 
immune system of the host. The recipient is prepared for 
the transplant by immunosuppressive treatment, usually 
by chemotherapy and/or radiation therapy, followed by the 
transfers of autologous hematopoietic cells (cell harvested 
from the recipient before patient conditioning) or allogeneic 
hematopoietic cells (cell harvested from donors rather than 
the recipient) to restore the host immune system.16 Preclinical 
studies have supported this rationale in two animal models.17 
Case series of patients undergoing allogeneic HSCT for 
malignancy or aplastic anemia revealed long-term remission 
of coexistent autoimmune diseases.18 In 1996, the first case 
of a patient with an autoimmune disease who underwent 
autologous hematopoietic stem cell transplantation was 
reported.19 Since then, over 1000 patients with severe or 
organ-threatening autoimmune disease have been treated 
with hematopoietic stem cell transplantation, mostly through 
autologous stem cell transplantation, due to concerns about 
an increased risk of graft versus host disease (GVHD) 
associated with allogeneic grafting. The transplant-related 
mortality observed in severe SSc patients has decreased 
significantly over time from 17% early on to 8.7% more 
recently.20,21 Two prospective controlled trials of HSCT in 
SSc are ongoing. The Autologous Stem Cell Transplantation 
International Scleroderma (ASTIS) trial (www.astistrial.
com) was launched in 2001 by the European Group for Blood 
and Marrow Transplantation (EBMT)/EULAR scleroderma 
study group, to compare the efficacy and safety of high 
dose immunoablation and HSCT with intravenous pulse 
therapy cyclophosphamide for the treatment of patients 
with severe SSc.22 The Scleroderma: Cyclophosphamide 
or Transplantation (SCOT) trial (www.sclerodermatrial.
org) is sponsored by the US National Institutes of Health 
(NIH), similarly to compare the efficacy and safety of 
hematopoietic cell transplantation following high-dose 
immunosuppressive therapy with monthly intravenous pulse 
cyclophosphamide.
In the past several years, multipotent mesenchymal 
stromal cells, also referred to as mesenchymal stem cells 
(MSCs) have attracted attention in the treatment of autoim-
mune diseases. Their availability, low toxicity, as well as 
antiproliferative, anti-inflammatory, and immunosuppressive 
properties have been explored in animal models and in 
patients with severe GVHD, and MSCs may be a potential treat-
ment option in patients with SSc, although data on the results 
of using MSCs in human autoimmune disease are scarce.
HSCT in systemic sclerosis
rationale for HSCT
Animal models with autoimmune diseases provided the 
rationale for HSCT. Investigations on hematopoietic 
chimeric rodents’ strains have revealed the important role of 
the hematopoietic system. The determinant of the suscepti-
bility or resistance to various autoimmune diseases in these 
chimeric animals relies on the genotype of the bone marrow, 
which led to the hypothesis that the underlying defect 
resides in the hematopoietic stem cell.23,24 The majority of 
preclinical experiments supported the rationale for HSCT 
with two animal models, adjuvant arthritis and experimental 
allergic encephalomyelitis (EAE) induced in Buffalo rats. 
In these strains, adjuvant arthritis is manifested as a chronic, 
progressive systemic polyarthritis which mostly resembles 
human rheumatoid arthritis (RA); experimental allergic 
encephalomyelitis induced in Buffalo rats is manifested as 
a chronic, remitting/relapsing form of encephalomyelitis 
resembling multiple sclerosis (MS). In nearly all rats 
with adjuvant arthritis and 70% of rats with EAE absence 
of spontaneous relapses was complete after autologous 
stem cell transplantations with total body irradiation.17 
Autologous HSCT was most successful at early disease 
stage, no effect was observed at more advanced stages. 
The success of treatment also depends on how completely 
the autoantigen-specif ic activated T-lymphocytes and 
memory cells are eradicated with increased intensity of 
conditioning therapy or certain conditioning agents.25 The 
stronger lympho-myeloablative regimens, like high-dose 
total body irradiation (TBI) (9–10 Gy) results in better 
response to HSCT; however, high-dose TBI is associated 
with serious late carcinogenic events.23 In both adjuvant 
arthritis and EAE models in Buffalo rats, cyclophospha-
mide alone or busulfan alone at the highest tolerated doses 
were less effective than high-dose TBI. Combination of 
cyclophosphamide with lower dose (4 Gy) TBI and the 
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combination of busulfan with cyclophosphamide were as 
effective as high-dose TBI.24
In comparison to autologous HSCT in animal models 
with EAE, allogeneic HSCT was found to be superior in 
terms of suppressing spontaneous relapse rates, 30% vs 
5% respectively.26,27 This may suggest that allogeneic donor 
T cells eliminate autoreactive host lymphocytes, and may 
induce tolerance to autoimmune epitopes by deletion of 
autoreactive repertoires, and therefore, mediate a form 
of immunotherapy termed graft-versus-autoimmunity 
(GVA).28,29 Animal studies also demonstrate that resistance 
to autoimmune disease resides and can be transferred by 
hematopoietic stem cells. Engraftment of allogeneic stems 
cells could result in tolerance to donor antigens, permit-
ting acceptance of donor-derived tissue without intensive 
immunosuppressive therapy.30 Thus animal studies support 
HSCT in autoimmune diseases with several potentially useful 
clinical strategies.
Although a putative GVA effect from allogeneic HSCT 
theoretically may be beneficial, the most significant toxicity 
of allogeneic HSCT is an immunologic reaction of donor 
cells against host tissues, a complication known GVHD, 
associated with significant morbidity and mortality. Most 
recently, several groups have used mini-conditioning with 
non-myeloablative or reduced-intensity conditioning in 
animal models, and human trials for allogeneic HSCT 
resulted in less GVHD, accompanied by the induction 
of transplantation tolerance and re-establishment of self-
tolerance with allogeneic mixed chimerism.31–33
Mechanistic aspects for HSCT
Currently, the most favored theory to support treatment with 
HSCT for autoimmune disease is that the reconstitution of the 
immune system from stem cells represents a recapitulation 
of ontogenesis and may be accompanied by the induction 
of self-tolerance from immune ablation and hematopoietic 
stem cells.
Potent immunosuppressive treatments with chemotherapy 
or TBI regimens can eliminate autoreactive memory B cells 
and T cells, thus “resetting” the immune system, that is, the 
elimination of T and/or B cell repertoires allows the patient’s 
immune system to “start from scratch” and regenerate 
normally. The function of pathogenic and new developing 
T cell clones may be altered or immunomodulated by the 
conditioning and hematopoietic stem cells. For example, 
a study investigated qualitative immunologic changes that 
are responsible for the induction of immune tolerance by 
autologous HSCT in patients with juvenile idiopathic RA 
undergoing autologous HSCT. The study demonstrated 
the rapid restoration of the frequency of FoxP3 expressing 
CD4+CD25bright regulatory T cells from severely reduced 
numbers before HSCT to normal levels after HSCT, and a 
renewed thymopoiesis of naïve mRNA FoxP3 expressing 
CD4+CD25+ regulatory T cells subsequently optimized the 
regulatory T cells repertoire and sustained the remission.34 
Alternative mechanisms involved in HSCT may include 
intrathymic deletion (or tolerance) of newly developing 
autoreactive T cells, anergy, and deletion of peripheral auto-/
allo reactive T cells, tolerization of B cells induction through 
mixed allogeneic chimerism, and B lymphoablation.35
Patient selection for HSCT
In general, the indication for HSCT in patients with SSc 
follows the consensus guidelines “life or organ threatening 
autoimmune diseases refractory to conventional therapy 
and with sufficient reversible pathology to allow a decent 
quality of life after cessation of inflammation”, in considering 
the morbidity and mortality associated with HSCT.36 
In November 2002, a meeting was held in Florence, Italy 
aiming to analyze existing data from patients transplanted 
for autoimmune disorders and to propose a safe approach to 
these patients in relation to cardiotoxicity. Cardiac assessment 
was considered a high priority in cyclophosphamide-treated 
SSc.37 A modification of the stepped approach to cardiac 
assessment in patients with SSc and MS, proposed in 2004, 
seems appropriate for all patients undergoing HSCT.38
A careful and thorough cardiac and pulmonary assessment 
prior to HSCT should be performed including a standard 
12-lead ECG, a trans-thoracic echocardiograph, 24 h Holter 
monitor, BNP or NT-proBNP and cardiac troponin I or T, 
coronary artery angiography or right heart catheterization 
if coronary artery disease or pulmonary hypertension are 
suspected, pulmonary function test, and thoracic high-
resolution computer tomography (HRCT). The specific 
clinical features of patients with SSc were associated with 
potential toxicity in phase I/II stem cell studies. For example, 
patients with a mean pulmonary artery pressure above 
50 mmHg by right heart catheterization or an ejection frac-
tion below 40% tended not to tolerate sepsis with neutropenic 
fever, which induces a hyperdynamic cardiac output. 
Additionally, patients with SSc-related cardiac or pulmonary 
disease are prone to deteriorate, due to a combination of 
drug-induced organ toxicity and volume overload seen 
during the mobilization stage and conditioning.36 In patients 
with SSc, any reduction in ejection fraction is likely to 
be associated also with significant diastolic dysfunction. 
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BNP or NT-proBNP is a more reliable test for screening 
patients for elevated filling pressures. An NT-proBNP 
level of 350 pg/mL has been identified as associated with 
an increased risk during HSCT. A level above 250 pg/mL 
has been identified as being associated with an increased 
mortality in patients with SSc-associated pulmonary artery 
hypertension.38 Furthermore, in patients prone to low-level 
myocardial injury, cardiac troponin (I or T) assays will detect 
patients in whom the probability of unforeseen cardiac 
events is greater. Therefore, echocardiography, and Holter 
monitoring, BNP or NT-proBNP and cardiac troponin I or T, 
and coronary angiography or right cardiac catheterization 
are recommended in patients with SSc prior to undergoing 
a HSCT.
Mobilization of hematopoietic stem cells
The most common peripheral blood stem cell (PBSC) 
mobilization regimen are single-agent granulocytes 
colony-stimulating factor (G-CSF) or cyclophosphamide 
and G-CSF, based on methods established for patients 
with non-autoimmune disorders.39 Flares of autoimmune 
diseases like RA and MS have occurred in patients taking 
G-CSF as a single regimen for mobilization, presented 
with transient swollen and tender joints in RA and serious 
and irreversible neurological deterioration in MS.40,41 
The only complication of G-CSF PBSC mobilization in 
patients with SSc was transient telangiectasias that spon-
taneously resolve. Patients with SSc with cardiac and/or 
pulmonary involvement undergoing PBSC with high-dose 
cyclophosphamide (4.0 g/m2) may have cardiac and/or 
pulmonary complications.40 After collection of progenitor 
cells, many groups perform ex vivo lymphocyte depletion. 
Aggressive lymphocyte depletion may increase the risk of 
post-transplantation opportunistic infections such as cyto-
megalovirus, fungemia, Pneumocystis carinii pneumonia, or 
Epstein-Barr virus post-transplantation lymphoproliferative 
disease (PTLD).39 The PBSC method, therefore, should be 
individualized for the disease and organ involved.
Conditioning regimens
Cyclophosphamide, cyclophosphamide I antithymocyte 
globulin (ATG), and cyclophosphamide/TBI/ATG have 
been commonly used as conditioning regimens for SSc.42–44 
As mentioned before, high-dose cyclophosphamide is 
associated with high cardiopulmonary mortality in patients 
with SSc.40 TBI without lung shielding has been asso-
ciated with lethal pulmonary deterioration in patients 
with pulmonary scleroderma.44 When using high-dose 
(40–70 Gy) localized radiation to treat cancer in patients 
with SSc, radiation-related injury may extend beyond the 
radiation field and cause death in approximately a third 
of patients and/or severe fibrosis in areas overlapping the 
radiation field.45 When using low-dose (18 Gy) radiation, 
patients with SSc may develop radiation-related toxicities 
that are difficult to distinguish from disease exacerbation.46 
The TBI-related lung injury may be lessened if partial lung 
shielding is used. One possible mechanism of radiation-
related injury is that radiation may be synergistic or 
additive to ongoing scleroderma-related vascular injury 
and tissue f ibrosis.47 The histological features of late 
radiation injury are similar to SSc, including a vasculopathy 
with loss of capillaries, telangiectasia, and excessive 
collagen deposition.48 Furthermore, because high-dose 
rabbit ATG has been reported to be associated with lethal 
PTLD, lower-dose rabbit ATG or the use of horse ATG are 
recommended.49 All patients should be warned of infertility, 
late toxicities like cataracts, or late malignancies from TBI 
and/or cyclophosphamide.50 Again, individualized condi-
tioning regimens need be designed to decrease the risk 
of organ damage and infection, and therefore minimize 
regimen-related morbidity and mortality.
Clinical trials and outcome
Autologous HSCT
Early phase I/II studies reported improved skin scores and 
activities of daily living but unchanged renal, cardiac, and 
pulmonary function. However, with intensive immunosup-
pressive regimens, these studies showed significantly high 
treatment-related mortality (TRM). In the first 41 trans-
planted patients with SSc after a median of 12 months of 
follow-up, as reported to the EBMT/EULAR database, an 
improvement of 25% or more in the skin score (measured 
by the modified Rodnan method) was seen in 70% of the 
patients, with a TRM observed initially at 17%, and later 
at 12.5% when an additional 24 patients were recruited.20 
Several protocols have been used; peripheral blood stem 
cell mobilization has been performed with cyclophospha-
mide alone or combined with granulocyte colony stimula-
tion factor. Seven conditioning regimens have been used 
including cyclophosphamide ± antithymocyte globulin ± 
total body irradiation. A long-term follow-up of this cohort 
reported a significant drop in skin score of 25% of initial 
values in 79% patients at 2 years and 60% patients at 3 years 
after HSCT. Complete and partial remission was observed 
in two-thirds of the patients up to 3 years after HSCT. The 
overall TRM was of 8.7%.21 The reduced TRM contributed 
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to more careful patient selection by careful cardiac and 
pulmonary function evaluation.
A US multicenter pilot study of 19 patients with SSc 
using a regimen of cyclophosphamide 120 mg/kg body 
weight, TBI 8 Gy, and equine ATG 90 mg/kg body weight and 
a CD 34+ selected graft product, showed a sustained improve-
ment in skin scores and overall function in 12 patients at 
a median follow-up of 14.7 months. Initially, 2/8 (25%) 
patients died of TBI-related interstitial pneumonitis. After 
amending the protocol with lung shielding, 2 of the last 
11 patients died, 1 from Epstein-Barr virus infection and 
1 from renal failure. Pulmonary function in 4/9 (44%) 
patients remained clinically unchanged (less than 15% 
variation), but declined in 5/9 (56%) patients.51 A long-term 
follow-up (median 4 years) of the US multicenter pilot 
study showed marked clinical improvement in skin and 
overall function (modified Health Assessment Questionnaire 
Disability index). Biopsies confirmed a statistically decrease 
of dermal fibrosis compared with baseline (P  0.001). 
Lung, heart, and kidney remained clinically stable. The 
overall TRM was of 23.5% (8/34).52 These data suggest that 
a myeloablative regimen containing TBI was associated 
with significant TBI-related pulmonary toxicity. A French 
cohort of 12 patients with refractory SSc was reported using 
a regimen of cyclophosphamide (4 g/m2) and recombinant 
human granulocyte colony-stimulating factor (5 µg/kg/day) 
with positive CD 34+ selection, conditioning used cyclophos-
phamide (200 mg/kg) or melphalan (140 mg/m2) according 
to cardiac function. After 18 months (range 1–26), 8 out 
of 11 patients have shown major or partial response, while 
5 relapsed within 1 year; there was 1 procedure-related 
death and 3 resulting from disease progression.53 Recently, 
a phase I non-myeloablative (without TBI) autologous 
HSCT study (n = 10) reported sustained improvement in 
skin score and stabilization in cardiac, pulmonary, and 
renal function after a median follow-up of 25.5 months. 
The overall TRM was 0. The overall and progression-free 
survival rates were 90% and 70% respectively.54 Furthermore, 
a long-term follow-up study with 26 patients with severe SSc 
in the Netherlands and France using a non-myeloablative 
conditioning regimen showed sustained improvement of skin 
thickening and stabilization of organ function after a median 
follow-up of 5.3 years. The overall survival rate at 5 years 
was 96.2% and at 7 years 84.8%.55 The data from these 
two studies suggest that a non-myeloablative conditioning 
regimen may result in improved skin flexibility similar to 
a myeloablative TBI-containing regimen, but without the 
toxicity and risks associated with TBI.
In terms of the efficacy of HSCT in SSc, most studies 
have demonstrated softening skin which paralleled capillary 
regeneration, reduced transcription of profibrotic genes, 
and remodeling of the vasculopathy and fibrosis.55–57 For 
example, a recent study showed improvement in microcircu-
lation measured by nail fold videocapillaroscopy (NVC) in 
patients with SSc. At 3 months after HSCT, the NVC pattern 
changed from “late pattern”, as avascular areas and vascular 
architecture disorganization, into “active pattern”, as frequent 
giant capillaries and active angiogenesis.57 One study reported 
using local injection of CD 34+ cells and mononuclear cells 
for ischemic skin ulcers in hands and lower extremities in 
patients with SSc, and showed rapid beneficial effect on 
vascular symptoms resulting in ulcer healing. The therapeu-
tic efficacy was associated with restoration of endothelial 
function, augmentation of microcirculatory blood flow, and 
significant increase in angiogenesis.58 A single-institution 
pilot study reported a significant and rapid decrease of the 
extent of pulmonary fibrosis associated with SSc observed 
on HRCT in 9 patients with severe diffuse SSc 6 months 
after autologous HSCT. The early treatment effects of HSCT 
on the extent of pulmonary fibrosis decreased over time and 
were transient in some patients after long-term follow up.59 
Additionally, a new study demonstrated immunological 
reconstitution obtained from suppression of thymic function 
after autologous HSCT in 10 patients with SSc, assessed by 
quantification of signal joint T cell receptor rearrangement 
excision circles (sjTREC).60
The protocols of the ASTIS and SCOT trials are similar 
in their selection criteria, primary outcome and control arms, 
but differs in the conditioning regimens. ASTIS utilizes 
cyclophosphamide 200 mg/kg body weight and rabbit ATG, 
and SCOT uses cyclophosphamide 129 mg/kg body weight, 
equine ATG, and radiation of 800 cGy (with shielding of the 
lungs and kidney).61 The ASTIS trial was launched in 2001. 
As of June 2008, 122 patients have been randomized in 
25 centers from 10 countries and allocated to either high-dose 
immunoablation followed by autologous stem cell transplan-
tation (66 patients) or pulse-therapy cyclophosphamide iv 
(56 patients). The aim of the trial is to compare the safety and 
efficacy of HSCT versus pulsed cyclophosphamide therapy 
in patients with severe SSc. The SCOT trial was planed to 
recruit 226 patients with diffuse SSc, randomly assigned in 
a 1:1 ratio to either high-dose immunosuppressive therapy 
with autologous stem cell transplantation or monthly iv 
pulse cyclophosphamide for 12 months. All subjects will be 
followed up to 44 months after randomization. The primary 
study endpoint for the SCOT study is “event-free” survival at 
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44 months after randomization. To date, over 4000 samples 
from 50 randomized subjects have been collected from base-
line and to time points through year 5 after randomization 
(www.sclerodermatrial.org). Both trials include extensive 
mechanistic studies relating to immune reconstitution, skin 
biopsy immunohistology, collagen and vascular remodeling, 
bronchoalveolar lavage cellular components, and HRCT lung 
changes.61 These clinical trials will determine whether HSCT 
yields sufficient clinical benefit to warrant further trials to 
enhance its efficacy and/or improve safety.
Allogeneic HSCT
The concept of allogeneic HSCT is total reconstitution of 
the immune cells with donor cells in order to eliminate 
autoreactive immune cells. However, myeloablative con-
ditioning and GVHD as a known complication carry a 
significant morbidity and mortality in patients with SSc. 
Four cases were reported, all of whom received a reduced 
intensity non-myeloablative HSCT.62–64 Three cases obtained 
successful responses (dramatically decreased skin score and 
stable pulmonary function) and 2 cases reported GVHD that 
developed in relation to allogeneic HSCT, one of whom died 
of complications related to acute GVHD. A multidisciplinary 
consensus group published a guideline for allogeneic HSCT 
in autoimmune diseases.65
Multipotent mesenchymal stromal 
cells (MSCs)
The plastic-adherent cells isolated from bone marrow and 
other sources have come to be widely known as multipotent 
MSCs, also referred as mesenchymal stem cells, although 
they are not true “stem cells”, as the biological properties of 
the unfractionated cells do not meet accepted criteria of stem 
cell activities. MSCs are capable of differentiating in vitro 
and in vivo to different MSC lineages, including adipose, 
bone, cartilage, muscle, and myelosupportive stroma. MSCs 
can be isolated from bone marrow, skeletal muscle, adipose 
tissue, synovial membranes, and other connective tissues of 
human adults as well as cord blood and placental products.66 
In vitro and in vivo studies from animal models and human 
tissues suggest that MSCs may possess antiproliferative, 
anti-inflammatory, and immunosuppressive properties. The 
first disease in which the therapeutic potential of MSCs was 
addressed was an EAE model of MS. When injected in mice 
with chronic EAE induced by the MOG 35–55 peptide, MSCs 
showed a strong migratory potential to the white matter. The 
clinical course of EAE was significantly improved in animals 
treated with purified MSCs after both intracerebroventricular 
and intravenous administration.67 The bone marrow-derived 
MSCs have been shown to suppress the proliferation of 
stimulated T lymphocytes in patients with autoimmune 
diseases including systemic lupus erythematosus, RA, 
dermatomyositis, or SSc.68 MSCs, therefore may be a poten-
tial treatment option in autoimmune diseases.61 Autologous 
bone marrow-derived MSCs in SSc patients have been shown 
to be normal with respect to proliferation, clonogenicity and 
differentiation to bone and fat.71 However, one study has 
shown defective differentiation into endothelial precursors 
in bone marrow-derived MSCs from SSc patients,70 which 
should be considered when choosing autologous or allogeneic 
MSCs sources for scleroderma treatment.
Several phase I and II trials have showed no acute or long-
term adverse events after ex vivo expanded allogeneic MSCs 
infused to promote hematopoietic recovery from autologous 
or allogeneic HSCT and to treat patients with osteogenesis 
imperfecta.71–76 Two cases reported successful treatment from 
infusion of in vitro expanded MSCs in patients with steroid-
resistant severe acute GVHD, a condition sharing similarities 
with SSc.77,78 One case report showed improvement in a 
patient with severe progressive SSc after transplantation of 
MSCs from an allogeneic haploidentical-related donor.79 
In a multicenter, phase II trial of MSCs for treatment of 
steroid-resistant severe acute GVHD, 55 patients received 
ex vivo expanded MSCs. Of these patients, 39/55 (71%) 
had either complete or partial responses, none had acute 
side effects during or immediately after infusion of MSCs, 
3/55 (7%) had recurrent malignant disease, and 1 developed 
de novo acute myeloid leukemia of recipient origin.80 The 
data suggested that MSCs derived from bone marrow might 
be a safe and effective treatment for patients with severe 
acute GVHD who do not respond to corticosteroid and other 
immunosuppressive therapies.
Few publications on the results of using MSCs in human 
autoimmune disease are available. Phase I/II clinical trials are 
underway in Crohn’s disease and MS and are being planned 
for systemic lupus erythematosus, SSc, vasculitis and other 
autoimmune diseases.81 Coordinated by the EBMT, an inter-
national interdisciplinary registry of MSC-treated patients 
has been launched to allow uniform collection of long-term 
safety data.82
Conclusion
Systemic sclerosis is an autoimmune connective tissue 
disorder of unknown causes characterized by humoral and 
cellular immune dysregulation, microvasculopathy, and 
progressive cutaneous and visceral fibrosis. Severe diffuse 
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SSc is associated with a mortality of 40% to 50% within 
5 years. In the past decade, HSCT has been explored for the 
treatment for autoimmune diseases including SSc. Studies 
in animal models showed that the transfer of hematopoietic 
stem cells may “reset” the immune reconstitution and 
induce the self-tolerance of autoreactive T and B cells. 
Phase I/II clinical trials in autologous HSCT for patients 
with SSc have shown a satisfactory benefit, including 
long-term improvement in skin thickening and stability of 
visceral organ involvement. The treatment-related mortality 
decreased from 17% to 8.7% with careful patient selection. 
Two ongoing prospective, randomized phase III trials 
(ASTIS and SCOT) will help to determine the efficacy and 
safety profile in patients with severe SSc after autologous 
HSCT. Only a few cases of successful responses have been 
reported with the use of allogeneic HSCT in SSc patients, 
but treatment-related complication like GHVD have been 
frequent. Recently, multipotent MSCs have shown promise 
as an antiproliferative, anti-inflammatory and immunosup-
pressive agent in phase II trials for patients with severe 
steroid-resistant acute GVHD, and may potentially open a 
new era of therapy for SSc.
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